NCT03426228 (IVF) is a clinical trial of HbA1C in GDM, sponsored by University of Warwick.

Who is sponsoring NCT03426228?

NCT03426228 is sponsored by University of Warwick.

What drugs are being tested in NCT03426228?

Interventions in NCT03426228: HbA1C.

What condition does NCT03426228 study?

NCT03426228 studies GDM, Insulin Resistance, Glucose Intolerance, PCOS, Obesity.

Is NCT03426228 still recruiting?

NCT03426228 is currently completed. Last updated 14 July 2021.

Are results published for NCT03426228?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-07-14 · How we verify

NCT03426228: IVF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

In Vitro Fertilization Impact on Metabolic Parameters

Completed Results posted Last updated 14 July 2021

What this trial tests

trial testing HbA1C in GDM in 344 participants. Completed in 5 January 2020.

Timeline

15 February 2018

Primary endpoint
1 August 2019

5 January 2020

Quick facts

Lead sponsor	University of Warwick
Status	Completed
Study type	OBSERVATIONAL
Enrollment	344
Start date	15 February 2018
Primary completion	1 August 2019
Estimated completion	5 January 2020
Sites	1 location across United Arab Emirates

Drugs / interventions tested

HbA1C

Conditions studied

GDM — all drugs for GDM →
Insulin Resistance — all drugs for Insulin Resistance →
Glucose Intolerance — all drugs for Glucose Intolerance →
PCOS — all drugs for PCOS →

Sponsor

University of Warwick

Who can join

Adults 18 to 39, female only, with GDM or Insulin Resistance. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Short-term Effect of Fertility Medications on Glucose Homeostasis and Insulin Resistance in Patients Undergoing IVF Treatment Primary · 12 weeks of pregnancy

Participants who experience an abnormal increase in fasting glucose (\>110) and A1C (\>5.7) will be identified post-treatment. Also, for those previously known to be insulin-resistant, HOMA ratio will help identifying whether the treatment worsens or has no effect on their insulin resistance state.

Glucose, fasting

Group	Value	95% CI
Non-Pregnant	87.62	79.3 – 95.9
Pregnant	82.19	75 – 89.4

Insulin, fasting

Group	Value	95% CI
Non-Pregnant	9.37	4.00 – 14.8
Pregnant	9.45	2.5 – 16.4

Effect of Fertility Medications on Lipids Profile Secondary · 12 weeks of pregnancy

Lipid profile will be measured before and after treatment; participants experiencing hypercholesterolemia post-treatment will be consulted by a dietitian to help them better manage the condition during their pregnancy (total chol, LDL and triglycerides)

Group	Value	95% CI
Pregnant	199.5	155.15 – 243.9
Non-pregnant	174.9	126.9 – 222.9

Effect of Fertility Medications on Thyroid Function Secondary · 12 weeks of pregnancy

TSH level will be measured pre- and post-IVF. Early diagnosis of thyroid dysfunction will be closely monitored with frequent repetitions of blood test, especially during the first trimester.

Group	Value	95% CI
Pregnant	1.36	0.26 – 2.46
Non-pregnant	1.80	0.75 – 2.85

Sponsor's own description

A quantitative prospective cohort study will be conducted, where blood samples will be collected at different timings during the IVF protocol, to assess the impact of fertility medications on metabolic parameters of patients undergoing IVF treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of HbA1C

Trials testing the same drug.

NCT06337825 — Object Assessment of Improvement in Non-Specific Symptoms After Parathyroidectomy for Primary Hyperparathyroidism · completed
NCT04070963 — Incidence of Poorly Controlled Diabetes in Surgical Population · unknown
NCT03834610 — Daily Oral L-arginine Plus Tadalafil in Diabetic Patients With Erectile Dysfunction · NA · completed

Other recruiting trials for GDM

Currently open trials in the same condition.

NCT06901791 — Efficacy of Lactobacillus Rhamnosus LRa05 in Gestational Diabetes · NA · recruiting
NCT06127823 — Effect of Intensive Nutrition Training, Education, and Support in Gestational Diabetes - The INTENSE-GDM TRIAL · NA · active not recruiting
NCT04192422 — DiGESTnewborn Study · recruiting

Other University of Warwick trials

Trials by the same sponsor.

NCT06334718 — Drone Delivered Defibrillators (The 3D Project). · completed
NCT05402436 — Breast Screening Atypia and Subsequent Development of Cancer in England · completed
NCT04977414 — Making Data Count Intervention Evaluation · NA · completed
NCT05046197 — Evaluating the Integration of the Recommended Summary Plan for Emergency Care Treatment (ReSPECT) Into Primary Care · completed
NCT05247463 — English Mammography Screening Outcomes by Age, Frequency and Test Threshold · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03426228 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Warwick
Last refreshed: 14 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03426228.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing